Ceva Santé Animale expands in North America with the acquisition of Artemis
This “strategic takeover” complements the French company’s portfolio and will also have a positive impact on its pet business.
The global veterinary health company is taking over Artemis Technologies, a Canadian company that has developed a rabies vaccine for certain wild animals.
This oral vaccine comes in the form of a capsule coated with a material that is palatable to the animal. Used for skunks and raccoons, it is used in Canada and the United States, where it has been tested for several years.
For Ceva, which already markets oral vaccines for foxes in Europe, the deal gives it access to complementary technology that will also have an application for pets.
“With this acquisition, we will help protect humans, wildlife, pets, and livestock from the devastating effects of this lethal zoonotic disease,” said Marc Prikazsky, President and CEO of Ceva Santé Animale.
Ceva Santé Animale posted a turnover of €1.4 billion ($1.48B) in 2022.
Share this story:
